SCHEMBL626000

SCHEMBL626000

Nc1nc(Cl)c2ncn([C@@H]3O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]3O)c2n1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NT5E P21589 2/20 0.77
P2RY1 P47900 9/20 0.70
P2RX3 P56373 4/20 0.70
P2RY11 Q96G91 3/20 0.70
ENPP1 P22413 2/20 0.70
P2RX1 P51575 2/20 0.70
P2RX4 Q99571 2/20 0.70
P2RY6 Q15077 1/20 0.70
P2RY12 Q9H244 1/20 0.68
P2RY2 P41231 2/20 0.66
P2RX2 Q9UBL9 2/20 0.66
SRC P12931 1/20 0.66
ALDH1A1 P00352 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
RNASEL Q05823 2/20 0.66
GPR17 Q13304 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14948859 1.00 NT5E (0.77) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL625828 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL17211052 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL12932283 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL3502237 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL29471291 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL18269547 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL13857854 0.92 P2RY1 (0.79) NT5EP2RY1P2RX3P2RY11ENPP1
SCHEMBL15305345 0.91 NT5E (0.84) NT5EP2RY1P2RY11P2RY2SRC
SCHEMBL16474336 0.91 NT5E (0.84) NT5EP2RY1P2RY11P2RY2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11998601-B2 Messenger RNA therapy for treatment of articular disease TRANSLATE BIO, INC. (US) 2024-06-04 US claimed
EP-3115064-B1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2021-11-24 EP claimed
US-11110156-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen CUREVAC AG (DE) 2021-09-07 US claimed
US-20210060181-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN CUREVAC AG (DE) 2021-03-04 US claimed
US-20210060175-A1 METHODS OF IMMUNOSTIMULATION WITH COMPLEXES OF RNA AND CATIONIC CARRIERS CUREVAC AG (DE) 2021-03-04 US claimed
US-10898589-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein Cure Vac AG (DE) 2021-01-26 US claimed
US-10799602-B2 Method for increasing expression of RNA-encoded proteins CUREVAC AG (DE) 2020-10-13 US claimed
US-10738306-B2 Artificial nucleic acid molecules for improved protein or peptide expression CUREVAC AG (DE) 2020-08-11 US claimed
US-10653799-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein CUREVAC AG (DE) 2020-05-19 US claimed
EP-3636669-A1 RNA-CODED ANTIBODY CureVac AG (DE) 2020-04-15 EP claimed
US-20160145346-A1 RNA-CODED ANTIBODY CUREVAC AG (DE) 2016-05-26 US claimed
US-9234013-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein CUREVAC AG (DE) 2016-01-12 US claimed
US-20150184195-A1 ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC GMBH (DE) 2015-07-02 US claimed
US-20150165006-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN Cure GmbH (DE) 2015-06-18 US claimed
US-20150093413-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN CUREVAC GMBH (DE) 2015-04-02 US claimed
US-20130195867-A1 RNA-CODED ANTIBODY CUREVAC GMBH (DE) 2013-08-01 US claimed
US-20100189729-A1 RNA-CODED ANTIBODY CURVAC GMBH (DE) 2010-07-29 US claimed
US-20100047261-A1 BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN CUREVAC GMBH (DE) 2010-02-25 US claimed
EP-2083851-A2 (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN Curevac GmbH (DE) 2009-08-05 EP claimed
WO-2008052770-A2 (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN CUREVAC GMBH (DE) 2008-05-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10653799-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein PARG, PARN, HNRNPH3 NT5E 891/4885P2RY1 1873/4885P2RX3 1798/4885
US-20150093413-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN HNRNPH3, PARG, CPSF6 NT5E 455/4885P2RY1 1936/4885P2RX3 1754/4885
US-20160145346-A1 RNA-CODED ANTIBODY TRDMT1, NSUN3, POLRMT NT5E 552/4885P2RY1 3643/4885P2RX3 2501/4885
US-20210060181-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN HNRNPH3, CPSF6, HNRNPL NT5E 325/4885P2RY1 2048/4885P2RX3 1904/4885
US-20150165006-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN NASP, H1-5, PARG NT5E 262/4885P2RY1 1538/4885P2RX3 1492/4885
US-10738306-B2 Artificial nucleic acid molecules for improved protein or peptide expression RNMT, NSUN3, RNGTT NT5E 155/4885P2RY1 2831/4885P2RX3 2043/4885
US-20100047261-A1 BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN RNMT, RNASE1, NSUN3 NT5E 1553/4885P2RY1 4557/4885P2RX3 4449/4885
US-10898589-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein HNRNPH3, HNRNPL, PABPC1 NT5E 791/4885P2RY1 3972/4885P2RX3 3766/4885
US-11998601-B2 Messenger RNA therapy for treatment of articular disease NSUN3, RNMT, TRDMT1 NT5E 1205/4885P2RY1 3509/4885P2RX3 2826/4885
US-10799602-B2 Method for increasing expression of RNA-encoded proteins STING1, UPF1, CUTA NT5E 2603/4885P2RY1 3890/4885P2RX3 3742/4885
US-11110156-B2 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen HNRNPH3, HNRNPL, CPSF6 NT5E 281/4885P2RY1 1808/4885P2RX3 1525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.